drugset / Trial / NCT00209664
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative gastric cancer
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | S-1 | Small molecule | — | — |